Results 21 to 30 of about 10,435 (208)
Perturbação psicótica aguda associada à vigabatrina.
Acta Médica Portuguesa, 2000 Vigabatrin, a drug mainly used in the treatment of therapy-resistant epilepsy, has been associated to a large range of adverse effects, including acute psychotic disorders. The authors report the case of a 44-year-old patient with drug-resistant temporal
M Xavier +3 more
doaj +1 more source
Modulation of the GABAergic pathway for the treatment of fragile X syndrome. [PDF]
, 2014 Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is caused by mutations on the fragile X mental retardation gene (FMR1) and lack of fragile X mental retardation ...
Hagerman, Randi J +2 more
core +1 more source
BMC Pediatrics, 2010 Background Infantile spasms represent a serious epileptic syndrome that occurs in the early infantile age. ACTH and Vigabatrin are actively investigated drugs in its treatment.
Ishaque Sidra +3 more
doaj +1 more source
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1996 ABSTRACT:Vigabatrin (VGB) is a recently-released antiepileptic drug which works by a clearlydefined mechanism of action: inhibition of GABA transaminase leading to an elevation of brain GABA concentration. It has been proven effective, mainly as an add-on agent, in complex partial and secondarily generalized seizures in both adults and children as well
openaire +2 more sources
Development of Acute Encephalopathy Due to Vigabatrin Use in a Case of Nonketotic Hyperglycinemia [PDF]
, 2012 A 3-month-old boy with early myoclonic epilepsy owing to nonketotic hyperglycinemia developed acute encephalopathy after - vigabatrin was presented. Due to the use of vigabatrin, the elevated gamma-aminobutyric acid (GABA) concentration in the brain ...
Elif YÜKSEL KARATOPRAK, Sema SALTIK
core +1 more source
Epilepsia, 1999 Summary:Vigabatrin (VGB) is a structural analogue of the inhibitory neurotransmitter γ‐amino butyric acid (GABA), which produces its antiepileptic effect by irreversibly inhibiting the degradative enzyme GABA‐transaminase. This produces an increase in central nervous system (CNS) GABA levels.
openaire +2 more sources
Vigabatrin-Induced Peripheral Visual Field Defects in Patients With Refractory Partial Epilepsy [PDF]
, 2010 Purpose: Vigabatrin can cause retinopathy, resulting in bilateral visual field constriction. Previous analyses of results from a prospective, observational study assessing vigabatrin-induced visual field constriction (described below) employed a ...
Bittman, Richard M. +3 more
core +2 more sources
Safety profile of oxcarbazepine: results from a prescription-event monitoring study [PDF]
, 2010 Purpose: To monitor safety of oxcarbazepine, prescribed in primary care in England, using prescription-event monitoring (PEM). Methods: Postmarketing surveillance using observational cohort technique of PEM.
Buggy, Y. +3 more
core +1 more source
Vigabatrin-induced retinal toxicity is partially mediated by signaling in rod and cone photoreceptors. [PDF]
PLoS ONE, 2012 Vigabatrin (VGB) is a commonly prescribed antiepileptic drug designed to inhibit GABA-transaminase, effectively halting seizures. Unfortunately, VGB treatment is also associated with the highest frequencies of peripheral visual field constriction of any ...
Jin Yang +7 more
doaj +1 more source
Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. [PDF]
, 2018 There is a need for treatments that can safely promote regulatory lymphocyte responses. T cells express GABA receptors (GABAA-Rs) and GABA administration can inhibit Th1-mediated processes such as type 1 diabetes and rheumatoid arthritis in mouse models.
Dang, Hoa +4 more
core +3 more sources